Research Area: Acute and Chronic Health Care

Publications by Topics

Topic: Prescription Drugs

Citation

Wallack SS, Thomas CP, Martin TC, Ryan A (2007). Differences in Prescription Drug Use in HMO and Self-insured Health Plans. Medical Care Research and Review 64 (1): 98-116.

Thomas CP, Wallack SS, Martin TC (2005). How Do Seniors Use Their Prescription Drug Discount Cards? Health Affairs Web Exclusive: W5-180-190.

Harris K, Thomas CP (2004). Naltrexone and Pharmacy Benefit Management. Journal of Addictive Diseases 23 (4): 11-29.

Simoni-Wastila L, Strickler G (2004). Risk Factors Associated with Problem Use of Prescription Drugs. American Journal of Public Health 94 (2): 266-268.

Wallack SS, Weinberg DB, Thomas CP (2004). Health Plans' Strategies to Control Prescription Drug Spending. Health Affairs 23 (6): 141-148.

Thomas CP (2003). Incentive-Based Formularies - Perspectives. The New England Journal of Medicine 349 (23): 2186-2188.

Thomas CP, Wallack SS, Leung MY, Ritter G (2003). PBM-Administered Prescription Drug Discount Cards: Savings for Uninsured Seniors. Waltham, MA: Schneider Institute for Health Policy, Heller School, Brandeis University; March 11.

Altman SH, Thomas CP (2002). Controlling Spending for Prescription Drugs - Editorial. The New England Journal of Medicine 346 (11): 855-856.

Ritter G, Thomas CP, Wallack SS (2002). Greater Use of Generics: a Prescription for Drug Cost Savings. Waltham, MA: Schneider Institute for Health Policy, Heller School, Brandeis University; February.

Thomas CP, Wallack SS, Lee S, Ritter G (2002). Impact of Health Plan Design and Management on Retirees' Prescription Drug Use and Spending, 2001. Health Affairs Web Exclusive: W408-W419.

Doonan M (2001). The Economics of Prescription Drug Pricing: A Background Paper. Waltham, MA: Council on the Economic Impact of Health System Change, Schneider Institute for Health Policy, Heller School, Brandeis University; March.

Rosman BP (2001). The Future of the American Hospital II: The Structure of the Hospital and the Industry - Background Paper. Washington, DC: Council on the Economic Impact of Health System Change, Schneider Institute for Health Policy, Heller School, Brandeis University; December.

Simoni-Wastila L, Tompkins CP (2001). Balancing Diversion Control and Medical Necessity: The Case of Prescription Drugs with Abuse Potential. Substance Use & Misuse 36 (9-10): 1275-1296.

Thomas CP, Ritter G, Wallack SS (2001). Growth in Prescription Drug Spending among Insured Elders. Health Affairs 20 (5): 265-277.

Wallack SS, Thomas CP, Ritter G (2001). Recent Trends in Prescription Drug Spending for Insured Individuals under 65 and Age 65 and Older. Waltham, MA: Schneider Institute for Health Policy, Heller School, Brandeis University; July 30.

Thomas CP, Ritter G (2000). Drug Utilization Trends by Therapeutic Class. Waltham, MA: Schneider Institute for Health Policy, Heller School, Brandeis University; for U.S. Department of Health & Human Services, Office of the Assistant Secretary for Planning and Evaluation; August.

Wallack SS (2000). Factors Driving Prescription Drug Expenditure Increases. Testimony before the Committee on Health, Education, Labor and Pensions, United States Senate. Washington, DC; July 18.

Wallack SS, Thomas CP, Hodgkin D, DiMasi J, Simoni-Wastila L, Rader A, Constantine R, Brown JS (2000). Prescription Drug Policy: Background Paper for the Princeton Conference. Washington DC: Council on the Economic Impact of Health System Change, Schneider Institute for Health Policy, Heller School, Brandeis University.

Thomas CP, Shactman D, Altman SH (1999). Health Status, Technological Innovation, and Health Care Expenditures - Background Paper. Washington, DC: Council on the Economic Impact of Health System Change, Institute for Health Policy, Heller School, Brandeis University; February.

Khandker RK, Simoni-Wastila LJ (1998). Differences in Prescription Drug Utilization and Expenditures between Blacks and Whites in the Georgia Medicaid Population. Inquiry-the Journal of Health Care Organization Provision and Financing 35 (1): 78-87.

Schulman S, Brunton S, Shepard DS, Jacobs RP, Gerstenblith G, Wilson M, Wagner SL (1998). The Hypertension Optimal Treatment (HOT) Study: Implications for Hypertension Management and the J-Shape Curve. American Journal of Managed Care 4 (12): S733-S740.

Shepard DS (1998). Book Review: Managing Medicines: Public Policy and Therapeutic Drugs ( P Davis). International Journal for Quality in Health Care 10 (2): 169.

Shepard DS, Hodgkin D, Wilson M, Messerli FH, Jacobs RP, Brunton S, Wagner SL (1998). Cost Effectiveness of Intensive Treatment of Hypertension. American Journal of Managed Care 4 (12 (Supplement)): S765-S770.

Altman SH, Reinhardt UE, eds. (1996). Strategic Choices for a Changing Health Care System. Chicago, IL: Health Administration Press. The Baxter Health Policy Review, Volume II.

Khandker RK, Simoni-Wastila L (1996). Utilization and Expenditures for Prescription Drugs in Eight State Medicaid Programs. Waltham, MA: Institute for Health Policy, Heller School, Brandeis University, for the U.S. Healthcare Financing Administration; February 26.

Wastila LJ, Bishop CE (1996). The Influence of Multiple Copy Prescription Programs on Analgesic Utilization. Journal of Pharmaceutical Care in Pain and Symptom Control 4 (3).

Topic: Medical Devices or Procedures

Citation

Mechanic R (2006). Coverage and Reimibursement in an Era of Personalized Medicine: Emerging Policy Issues in Genetic Testing. Waltham, MA: Health Industry Forum, Schneider Institutes for Health Policy, Heller School, Brandeis University; October.

Tompkins CP, Altman SH, Eilat E (2006). The Precarious Pricing System for Hospital Services. Health Affairs 25 (1): 45-56.

Capitman J, Bhalotra S, Ruwe M (2005). Cancer and Elders of Color: Opportunities for Reducing Health Disparities: Evidence Review and Recommendations for Research and Policy. Burlington VT: Ashgate Publishing Company.

McCarty D, Clancy C (2002). Telehealth: Implications for Social Work Practice. Social Work 47 (2): 153-161.

Mechanic RE (2001). Proactive Medical Management. Cambridge, MA: Forrester Research; April.

Prottas J (2000). Rationing Human Organs for Transplant. In: Finkelstein N, ed. Transparency in Public Policy: Great Britain and the United States. New York, NY: St. Martin Press, 70-92.

Altman SH, Reinhardt UE, eds. (1996). Strategic Choices for a Changing Health Care System. Chicago, IL: Health Administration Press. The Baxter Health Policy Review, Volume II.

Research Area: Behavioral Health

Publications by Topics

Topic: Prescription Drugs

Citation

Hodgkin D, Horgan CM, Garnick D, Merrick E, Volpe-Vartanian J (2007). Management of Access to Branded Psychotropic Medications in Private Health Plans. Clinical Therapeutics 29 (2): 371-380.

Hall W, Doran C, Degenhardt L, Shepard DS (2006). Illicit Opiate Abuse. In: Jamison D, et al., eds. Disease Control Priorities in Developing Countries. 2nd Edition ed. New York: Oxford University Press, 907-932.

Thomas CP, Conrad P, Casler R, Goodman E (2006). Trends in the Use of Psychotropic Medications Among Adolescents, 1994 to 2001. Psychiatric Services 57 (1): 63-69.

Shevitz AH, Wilson IB, McDermott AY, Spiegelman D, Skinner SC, Antonsson K, Layne JE, Beaston-Blaakman A, Shepard DS, Gorbach SL (2005). A Comparison of the Clinical and Cost-Effectiveness of 3 Intervention Strategies for AIDS Wasting. Journal of Acquired Immune Deficiency Syndrome 38 (4): 399-406.

Harris K, Thomas CP (2004). Naltrexone and Pharmacy Benefit Management. Journal of Addictive Diseases 23 (4): 11-29.

Simoni-Wastila L, Ross-Degnan D, Mah C, Gao XM, Brown J, Cosler LE, Fanning T, Gallagher P, Salzman C, Soumerai SB (2004). A Retrospective Data Analysis of the Impact of the New York Triplicate Prescription Program on Benzodiazepine Use in Medicaid Patients with Chronic Psychiatric and Neurologic Disorders. Clinical Therapeutics 26 (2): 322-336.

Simoni-Wastila L, Ritter G, Strickler G (2004). Gender and Other Factors Associated with the Nonmedical Use of Abusable Prescription Drugs. Substance Use & Misuse 39 (1): 1-23.

Simoni-Wastila L, Strickler G (2004). Risk Factors Associated with Problem Use of Prescription Drugs. American Journal of Public Health 94 (2): 266-268.

Thomas CP, McCarty D (2004). Adoption of Drug Abuse Treatment Technology in Specialty and Primary Care. In: Harwood HJ, Myers TG, eds. In: New Treatments for Addiction: Behavioral, Ethical, Legal, and Social Questions. Washington, DC: National Academies Press, 140-172.

Horgan CM, Merrick EL, Garnick DW, Hodgkin D, Cenczyk R, Lusenhop RW, Bhalotra S (2003). The Provision of Mental Health Services in Managed Care Organizations. Rockville, MD: Center for Mental Health Services, Substance Abuse and Mental Health Services Administration. DHHS Publication Number (SMA) 03-3797.

Thomas CP, Wallack SS, Lee S, McCarty D, Swift R (2003). Research to Practice: Adoption of Naltrexone in Alcoholism Treatment. Journal of Substance Abuse Treatment 24 (1): 1-11.

Shepard DS, Beaston-Blaakman A (2002). Phase II Final Technical Report. Spending Estimates Reconciliation Project. Waltham, MA: Schneider Institute for Health Policy, Heller School, Brandeis University.

Simoni-Wastila L (2001). Application of Pharmacoeconomics: Cost-Effectiveness Analysis in Behavioral Health. In: Bogenberg FR, ed. Introduction to Applied Pharmacoeconomics. New York, NY: McGraw-Hill, Medical Publishing Division, 126-143.

Simoni-Wastila L, Tompkins CP (2001). Balancing Diversion Control and Medical Necessity: The Case of Prescription Drugs with Abuse Potential. Substance Use & Misuse 36 (9-10): 1275-1296.

Thomas CP, Wallack SS (2001). Economic Factors in Adoption of New Alcoholism Treatment Medications. The Economics of Neuroscience 2001 3 (12): 52-57.

Simoni-Wastila L (2000). The Use of Abusable Prescription Drugs: The Role of Gender. Journal of Womens Health & Gender-Based Medicine 9 (3): 289-297.

Wallack SS (2000). Factors Driving Prescription Drug Expenditure Increases. Testimony before the Committee on Health, Education, Labor and Pensions, United States Senate. Washington, DC; July 18.

Simoni-Wastila L (1998). Gender and Psychotropic Drug Use. Medical Care 36 (1): 88-94.

Topic: Medical Devices or Procedures

Citation

Horgan CM, Merrick E, Reif S, Stewart M (2007). Data Points: Internet-based Behavioral Health Services in Health Plans. Psychiatric Services 58 (3): 307.

Krevor BS, Capitman J, Oblak L, Cannon JB, Ruwe M (2003). Preventing Illegal Tobacco and Alcohol Sales to Minors through Electronic Age-Verification Devices: a Field Effectiveness Study. Journal of Public Health Policy 24 (3-4): 251-268.

Krevor BS (2002). Preventing Illegal Alcoholic Beverage and Tobacco Sales to Minors through Electronic Age Verification Devices: A Field Effectiveness Study. Waltham, MA: Schneider Institute for Health Policy, Heller School, Brandeis University for the Miller Brewing Company; January.

Simoni-Wastila L, Tompkins CP (2001). Balancing Diversion Control and Medical Necessity: The Case of Prescription Drugs with Abuse Potential. Substance Use & Misuse 36 (9-10): 1275-1296.

Research Area: International Health

Publications by Topics

Topic: Immunizations

Citation

Shepard DS, Suaya JA, Halstead SB, Nathan MB, Gubler DJ, Mahoney RT, Wang DN, Meltzer MI (2004). Cost-Effectiveness of a Pediatric Dengue Vaccine. Vaccine 22 (9-10): 1275-1280.

Topic: Medical Devices or Procedures

Citation

Prottas J (2000). Rationing Human Organs for Transplant. In: Finkelstein N, ed. Transparency in Public Policy: Great Britain and the United States. New York, NY: St. Martin Press, 70-92.